Location · Memphis, TN
Clinical trials in Memphis, TN
165 recruiting studies have a site in the Memphis area, and 38 of them accept healthy volunteers. The area includes Germantown, Collierville, Cordova, Bartlett, Southaven, MS, Olive Branch, MS and nearby cities.
165 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
Boehringer Ingelheim
- Location
- Birmingham, AL + 56 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
Novartis Pharmaceuticals
- Location
- Anniston, AL + 20 other US sites
- Eligibility basics
- Ages 12–100
- RecruitingPhase 3
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
AstraZeneca
- Location
- Alexander City, AL + 93 other US sites
- Eligibility basics
- Ages 18–130
- RecruitingPhase 3
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Regeneron Pharmaceuticals
- Location
- Chandler, AZ + 144 other US sites
- Eligibility basics
- Ages 50–85
- RecruitingPhase 3
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
Cytokinetics
- Location
- Alexander City, AL + 80 other US sites
- Eligibility basics
- Ages 18–85
- RecruitingPhase 3
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
Sanofi
- Location
- Scottsdale, AZ + 33 other US sites
- Eligibility basics
- Ages 1–25
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Novartis Pharmaceuticals
- Location
- Birmingham, AL + 42 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
Hoffmann-La Roche
- Location
- Guntersville, AL + 44 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
Axsome Therapeutics, Inc.
- Location
- Tucson, AZ + 35 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
Janssen Research & Development, LLC
- Location
- Anaheim, CA + 23 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
Novartis Pharmaceuticals
- Location
- Peoria, AZ + 19 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
DReAMzz- Dronabinol and Acetazolamide Medication for Sleep Apnea (ZZ). Dose Confirmation Crossover Study for IHL-42X in Subjects With Obstructive Sleep Apnea.
Incannex Healthcare Ltd
- Location
- Chula Vista, CA + 11 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)
Axsome Therapeutics, Inc.
- Location
- Dothan, AL + 28 other US sites
- Eligibility basics
- Ages 6–11
- RecruitingPhase 3
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)
Axsome Therapeutics, Inc.
- Location
- Dothan, AL + 27 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
Studying NMDA and Sigma-1 in Smoking Cessation Treatment (SUMMIT)
Axsome Therapeutics, Inc.
- Location
- Little Rock, AR + 24 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis
Novartis Pharmaceuticals
- Location
- Memphis, TN + 2 other US sites
- Eligibility basics
- Ages 18–100
- Recruiting
The Artisse™ Intrasaccular Device is Indicated for the Treatment of Wide-neck Bifurcating Intracranial Aneurysms (IAs).
Medtronic Neurovascular Clinical Affairs
- Location
- Los Angeles, CA + 24 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Incyte Corporation
- Location
- Birmingham, AL + 36 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 1
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)
Genentech, Inc.
- Location
- Peoria, AZ + 11 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Grifols Therapeutics LLC
- Location
- Rancho Mirage, CA + 7 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients
Aspeya, Inc.
- Location
- Phoenix, AZ + 19 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
Eli Lilly and Company
- Location
- Scottsdale, AZ + 36 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 2
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
Eli Lilly and Company
- Location
- Huntsville, AL + 28 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Eli Lilly and Company
- Location
- Dothan, AL + 36 other US sites
- Eligibility basics
- Ages 18–70